Compare UBSI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBSI | BLCO |
|---|---|---|
| Founded | 1982 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | 1994 | 2022 |
| Metric | UBSI | BLCO |
|---|---|---|
| Price | $48.11 | $16.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $43.17 | $18.45 |
| AVG Volume (30 Days) | ★ 1.0M | 359.4K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 18.91 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | $311,957,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $10.13 | $8.65 |
| Revenue Next Year | $5.36 | $5.59 |
| P/E Ratio | $53.71 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $34.10 | $13.09 |
| 52 Week High | $48.22 | $18.92 |
| Indicator | UBSI | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 54.48 |
| Support Level | $43.29 | $16.26 |
| Resistance Level | $48.22 | $16.64 |
| Average True Range (ATR) | 0.80 | 0.45 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 94.31 | 52.80 |
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.